Asia Pacific Crispr And Cas Genes Market Size & Outlook
Asia Pacific crispr and cas genes market, 2018-2030 (US$M)
Related Markets
Asia Pacific crispr and cas genes market highlights
- The Asia Pacific crispr and cas genes market generated a revenue of USD 1,180.2 million in 2024.
- The market is expected to grow at a CAGR of 18.4% from 2025 to 2030.
- In terms of segment, product was the largest revenue generating product & service in 2024.
- Service is the most lucrative product & service segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2030.
Asia Pacific data book summary
| Market revenue in 2024 | USD 1,180.2 million |
| Market revenue in 2030 | USD 3,185.9 million |
| Growth rate | 18.4% (CAGR from 2025 to 2030) |
| Largest segment | Product |
| Fastest growing segment | Service |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Product, Service |
| Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 25.2% of the global crispr and cas genes market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,185.9 million by 2030.
Product was the largest segment with a revenue share of 89.83% in 2024. Horizon Databook has segmented the Asia Pacific crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
Asia Pacific’s market is expected to witness lucrative growth over the forecast period. Factors responsible for this growth, include growing popularity of this technology in Asian therapeutics space and ongoing clinical trials in the region.
The regional market is anticipated to benefit greatly from the initiation of conferences & interventions in Asian countries, on current trends and future potential of gene editing tools. For instance, the 7th Plant Genomics and Gene Editing Congress.
Asia is expected to be conducted in September 2020 in Bangkok, Thailand. This conference covered various aspects of genetic engineering and CRISPR technology applied to specific crops, such as cannabis, orchids, wheat, apple, and maize, to improve their traits.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
CRISPR And Cas Genes Market Scope
CRISPR And Cas Genes Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific crispr and cas genes market size, by country, 2018-2030 (US$M)
Asia Pacific CRISPR And Cas Genes Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
